Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, Biocon has informed about submission of the press release titled ‘Biocon’s Malaysia Insulin Glargine Manufacturing Facility Receives EU GMP Certification, Provides Fillip to its Capacity’. The above information will also be available on the website of the Company at www.biocon.com.
The above information is a part of company’s filings submitted to BSE.
